Quizartinib (Daiichi Sankyo) is an oral multi-tyrosine kinase inhibitor of the platelet-derived growth factor receptor, KIT/c-KIT, and FMS-like tyrosine kinase 3 (FLT3) receptor. Mutations in the FLT3 gene are found in more than 30% of patients with acute myeloid leukemia and result in disruption of the secondary structure of the tyrosine kinase, which often leads to constitutive receptor activation and unregulated cell signaling. Quizartinib exerts its anti-tumor activity by binding to the FLT3 receptor and inhibiting phosphorylation, resulting in the inhibition of receptor activation.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.